Quotient Clinical reports another successful year of record growth

Quotient Clinical, the Translational Pharmaceutics^® Company, announces another strong year of progress and growth. Quotient’s Translational Pharmaceutics platform has been adopted by more than 30 new customers – ranging from top 20 pharma companies to emerging biotech organizations – contributing to a year-on-year increase in revenue of 24%, with similar growth levels anticipated in the next 12 months. In addition, a significant proportion of studies begun in 2015 were from returning customers, with repeat business wins at record levels.

The company’s operational excellence and quality have been endorsed by successful routine GMP and GCP MHRA inspections and more than 50 client audits. There have also been over 20 case studies presented at leading scientific conferences, validating the time and cost savings that Quotient Clinical consistently delivers.

In response to the growing demand for its services, a significant investment program planned for the next 12 months will more than double Quotient’s operating capacity. Mark Egerton, CEO of Quotient Clinical, commented: “We have made significant progress over the past 12 months surpassing all expectations, with growth rates well above industry norms. Our growing customer base, coupled with the positive dynamics of the pharma R&D outsourcing market, have been the key drivers behind our decision to increase our operating capacity. We have repeatedly demonstrated that Translational Pharmaceutics can deliver significant time and cost savings for our clients, helping them to increase their overall R&D productivity. We look forward to another exciting year ahead, and to strengthening our relationships with our customers, helping to transform drug development with our science and innovation.”